List of Chapters/Sections(Table Of Content)
1 Inactivated Influenza Vaccine Market Overview
1.1 Product Overview and Scope of Inactivated Influenza Vaccine
1.2 Inactivated Influenza Vaccine Segment by Type
1.2.1 Global Inactivated Influenza Vaccine Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Trivalent Influenza Vaccine
1.2.3 Quadrivalent Influenza Vaccine
1.3 Inactivated Influenza Vaccine Segment by Application
1.3.1 Global Inactivated Influenza Vaccine Sales Comparison by Application: (2022-2028)
1.3.2 Children
1.3.3 Adolescence
1.3.4 Adults
1.3.5 Elderly
1.4 Global Inactivated Influenza Vaccine Market Size Estimates and Forecasts
1.4.1 Global Inactivated Influenza Vaccine Revenue 2017-2028
1.4.2 Global Inactivated Influenza Vaccine Sales 2017-2028
1.4.3 Inactivated Influenza Vaccine Market Size by Region: 2017 Versus 2021 Versus 2028
2 Inactivated Influenza Vaccine Market Competition by Manufacturers
2.1 Global Inactivated Influenza Vaccine Sales Market Share by Manufacturers (2017-2022)
2.2 Global Inactivated Influenza Vaccine Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Inactivated Influenza Vaccine Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Inactivated Influenza Vaccine Manufacturing Sites, Area Served, Product Type
2.5 Inactivated Influenza Vaccine Market Competitive Situation and Trends
2.5.1 Inactivated Influenza Vaccine Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Inactivated Influenza Vaccine Players Market Share by Revenue
2.5.3 Global Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Inactivated Influenza Vaccine Retrospective Market Scenario by Region
3.1 Global Inactivated Influenza Vaccine Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Inactivated Influenza Vaccine Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Inactivated Influenza Vaccine Market Facts & Figures by Country
3.3.1 North America Inactivated Influenza Vaccine Sales by Country
3.3.2 North America Inactivated Influenza Vaccine Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Inactivated Influenza Vaccine Market Facts & Figures by Country
3.4.1 Europe Inactivated Influenza Vaccine Sales by Country
3.4.2 Europe Inactivated Influenza Vaccine Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Inactivated Influenza Vaccine Market Facts & Figures by Region
3.5.1 Asia Pacific Inactivated Influenza Vaccine Sales by Region
3.5.2 Asia Pacific Inactivated Influenza Vaccine Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Inactivated Influenza Vaccine Market Facts & Figures by Country
3.6.1 Latin America Inactivated Influenza Vaccine Sales by Country
3.6.2 Latin America Inactivated Influenza Vaccine Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Inactivated Influenza Vaccine Market Facts & Figures by Country
3.7.1 Middle East and Africa Inactivated Influenza Vaccine Sales by Country
3.7.2 Middle East and Africa Inactivated Influenza Vaccine Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Inactivated Influenza Vaccine Historic Market Analysis by Type
4.1 Global Inactivated Influenza Vaccine Sales Market Share by Type (2017-2022)
4.2 Global Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2022)
4.3 Global Inactivated Influenza Vaccine Price by Type (2017-2022)
5 Global Inactivated Influenza Vaccine Historic Market Analysis by Application
5.1 Global Inactivated Influenza Vaccine Sales Market Share by Application (2017-2022)
5.2 Global Inactivated Influenza Vaccine Revenue Market Share by Application (2017-2022)
5.3 Global Inactivated Influenza Vaccine Price by Application (2017-2022)
6 Key Companies Profiled
6.1 CSL Limited
6.1.1 CSL Limited Corporation Information
6.1.2 CSL Limited Description and Business Overview
6.1.3 CSL Limited Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.1.4 CSL Limited Inactivated Influenza Vaccine Product Portfolio
6.1.5 CSL Limited Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.2.4 GSK Inactivated Influenza Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi Pasteur
6.3.1 Sanofi Pasteur Corporation Information
6.3.2 Sanofi Pasteur Description and Business Overview
6.3.3 Sanofi Pasteur Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Sanofi Pasteur Inactivated Influenza Vaccine Product Portfolio
6.3.5 Sanofi Pasteur Recent Developments/Updates
6.4 Viatris
6.4.1 Viatris Corporation Information
6.4.2 Viatris Description and Business Overview
6.4.3 Viatris Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Viatris Inactivated Influenza Vaccine Product Portfolio
6.4.5 Viatris Recent Developments/Updates
6.5 Hualan Biological
6.5.1 Hualan Biological Corporation Information
6.5.2 Hualan Biological Description and Business Overview
6.5.3 Hualan Biological Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Hualan Biological Inactivated Influenza Vaccine Product Portfolio
6.5.5 Hualan Biological Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.6.4 AstraZeneca Inactivated Influenza Vaccine Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Sinovac Biotech
6.6.1 Sinovac Biotech Corporation Information
6.6.2 Sinovac Biotech Description and Business Overview
6.6.3 Sinovac Biotech Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Sinovac Biotech Inactivated Influenza Vaccine Product Portfolio
6.7.5 Sinovac Biotech Recent Developments/Updates
6.8 Aleph Biomedical
6.8.1 Aleph Biomedical Corporation Information
6.8.2 Aleph Biomedical Description and Business Overview
6.8.3 Aleph Biomedical Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Aleph Biomedical Inactivated Influenza Vaccine Product Portfolio
6.8.5 Aleph Biomedical Recent Developments/Updates
6.9 Abbott Laboratories
6.9.1 Abbott Laboratories Corporation Information
6.9.2 Abbott Laboratories Description and Business Overview
6.9.3 Abbott Laboratories Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Abbott Laboratories Inactivated Influenza Vaccine Product Portfolio
6.9.5 Abbott Laboratories Recent Developments/Updates
6.10 Novartis International
6.10.1 Novartis International Corporation Information
6.10.2 Novartis International Description and Business Overview
6.10.3 Novartis International Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Novartis International Inactivated Influenza Vaccine Product Portfolio
6.10.5 Novartis International Recent Developments/Updates
7 Inactivated Influenza Vaccine Manufacturing Cost Analysis
7.1 Inactivated Influenza Vaccine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Inactivated Influenza Vaccine
7.4 Inactivated Influenza Vaccine Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Inactivated Influenza Vaccine Distributors List
8.3 Inactivated Influenza Vaccine Customers
9 Inactivated Influenza Vaccine Market Dynamics
9.1 Inactivated Influenza Vaccine Industry Trends
9.2 Inactivated Influenza Vaccine Market Drivers
9.3 Inactivated Influenza Vaccine Market Challenges
9.4 Inactivated Influenza Vaccine Market Restraints
10 Global Market Forecast
10.1 Inactivated Influenza Vaccine Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Inactivated Influenza Vaccine by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Inactivated Influenza Vaccine by Type (2023-2028)
10.2 Inactivated Influenza Vaccine Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Inactivated Influenza Vaccine by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Inactivated Influenza Vaccine by Application (2023-2028)
10.3 Inactivated Influenza Vaccine Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Inactivated Influenza Vaccine by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Inactivated Influenza Vaccine by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
